Clinical trials: Resistant Pneumonia
Covid19
Microbial Infection and AMR in Hospitalized Patients With Covid 19
To detect microbial infection and AMR associated with COVID 19 infection. To correlate risk factors of COVID 19 patients with microbial infections and their effects on disease.
- Trial name
- NCT04479982
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Assiut University
Pneumonia, Pulmonary Tuberculosis
Interferon Gamma for Drug Resistant Tuberculosis
This study will determine what dose of recombinant interferon-gamma is safe and effective for treating multiple drug-resistant tuberculosis.
- Trial name
- NCT00001407
- Testing
- Interferon Gamma
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pneumonia, Pneumococcal, Community-acquired Pneumonia
Quantitative Polymerase Chain Reaction for Improved Detection of Pneumococci in CAP "CAPTAIN"
The purpose of this study is to evaluate the added diagnostic value of a quantitative polymerase chain reaction targeting the lytA gene in detecting pneumococci in patients with community-acquired pneumonia.
- Trial name
- CAPTAIN (NCT03315403)
- Testing
- LytA targeted quantitative polymerase chain reaction (qPCR)
- Where
- 2 sites in Netherlands
- Volunteers
- 922 people, healthy volunteers welcome
- Sponsor
- Medical Center Alkmaar
Hospital Acquired Pneumonia, Ventilator Acquired Pneumonia
Real-World Study of Ceftazidime Avibactam in China
This observational study will enroll approximately 450 in patients. Patients treated with CAZ AVI for at least 1 dose at around 20 research centers in China will be enroll.
- Conditions
- Hospital Acquired Pneumonia, Ventilator Acquired Pneumonia, Complicated Intra Abdominal Infections
- Trial name
- REACT (NCT05487586)
- Testing
- ceftazidime avibactam group
- Where
- 17 sites in China
- Volunteers
- 220 people
- Sponsor
- Pfizer